Drug intelligence / Profile preview

NN-4103

Development stage: Unknown
Lead developer: Novelty Nobility
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

NN-4103 is a bispecific antibody drug candidate developed by Novelty Nobility. Its mechanism of action involves modulation of c-Kit (stem cell growth factor receptor), classifying it as a c-Kit modulator. The drug is being investigated primarily for the treatment of geographic atrophy, an advanced form of age-related macular degeneration. As of April 2025, its highest global R&D status is "Discovery," indicating preclinical or very early-stage development[1].

Targets

KIT (c-KIT proto-oncogene receptor tyrosine kinase)

Beyond the preview

Go deeper on NN-4103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NN-4103.

Explore the full profile